Enigma Diagnostics Limited

LONDON and OXFORD, England, August 10, 2011 - Enigma Diagnostics Limited (Enigma) and GlaxoSmithKline (GSK) today announced that they have signed agreements for the supply and commercialization on an exclusive basis of the Enigma ML system in Europe and other designated key countries, including India, Brazil and Russia.

OXFORD, England, July 18, 2011 - In October 2007, Enigma Diagnostics (Porton Down, UK & San Diego, USA) announced the award of a euro 3 Million grant by the European Commission Framework 7 programme.

MILTON PARK, OXFORD, England and SAN DIEGO, April 11, 2011 - Enigma Diagnostics announced today that it has commenced clinical trials for its intended point of care Enigma(R) ML Influenza A/B detection assay.

MANNEDORF, Switzerland, January 11, 2011 - The Tecan Group (SIX Swiss Exchange: TECN), a leading global provider of laboratory instruments and solutions, and Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the signing of a licence and collaboration agreement.

OXFORD, England, October 18, 2010 - Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced that the UK Intellectual Property Office (IPO) has rejected a revocation action brought by Biogene against three patents licensed exclusively to Enigma by the Defence Science and Technology Laboratory (Dstl), part of the UK Ministry of Defence.